Jonathan Pollack

Publications

• Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types. Giacomini CP, Sun S, Varma S, Shain AH, Giacomini MM, Balagtas J, Sweeney RT, Lai E, Del Vecchio CA, Forster AD, Clarke N, Montgomery KD, Zhu S, Wong AJ, van de Rijn M, West RB, Pollack JR. PLoS Genet. 2013; 9 (4): e1003464
• The spectrum of SWI/SNF mutations, ubiquitous in human cancers. Shain AH, Pollack JR. PLoS One. 2013; 8 (1): e55119
• CDX2 is an amplified lineage-survival oncogene in colorectal cancer. Salari K, Spulak ME, Cuff J, Forster AD, Giacomini CP, Huang S, Ko ME, Lin AY, van de Rijn M, Pollack JR. Proc Natl Acad Sci U S A. 2012; 109 (46): E3196-205
• Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, Maitra A, Pollack JR. Proc Natl Acad Sci U S A. 2012; 109 (5): E252-9
• EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms. Del Vecchio CA, Giacomini CP, Vogel H, Jensen KC, Florio T, Merlo A, Pollack JR, Wong AJ. Oncogene. 2012
• Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Huang S, Gulzar ZG, Salari K, Lapointe J, Brooks JD, Pollack JR. Oncogene. 2012; 31 (37): 4164-70
• A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. Malhotra S, Lapointe J, Salari K, Higgins JP, Ferrari M, Montgomery K, van de Rijn M, Brooks JD, Pollack JR. PLoS One. 2011; 6 (5): e20293
• SMURF1 amplification promotes invasiveness in pancreatic cancer. Kwei KA, Shain AH, Bair R, Montgomery K, Karikari CA, van de Rijn M, Hidalgo M, Maitra A, Bashyam MD, Pollack JR. PLoS One. 2011; 6 (8): e23924
• DR-Integrator: a new analytic tool for integrating DNA copy number and gene expression data. Salari K, Tibshirani R, Pollack JR. Bioinformatics. 2010; 26 (3): 414-6
• Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Tseng WW, Winer D, Kenkel JA, Choi O, Shain AH, Pollack JR, French R, Lowy AM, Engleman EG. Clin Cancer Res. 2010; 16 (14): 3684-95
• Focal amplification and oncogene dependency of GAB2 in breast cancer. Bocanegra M, Bergamaschi A, Kim YH, Miller MA, Rajput AB, Kao J, Langerød A, Han W, Noh DY, Jeffrey SS, Huntsman DG, Børresen-Dale AL, Pollack JR. Oncogene. 2010; 29 (5): 774-9
• Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Kim YH, Kwei KA, Girard L, Salari K, Kao J, Pacyna-Gengelbach M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, Minna JD, Pollack JR. Oncogene. 2010; 29 (10): 1421-30
• Genomic instability in breast cancer: pathogenesis and clinical implications. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. Mol Oncol. 2010; 4 (3): 255-66
• KIT mutations confer a distinct gene expression signature in core binding factor leukaemia. Lück SC, Russ AC, Du J, Gaidzik V, Schlenk RF, Pollack JR, Döhner K, Döhner H, Bullinger L. Br J Haematol. 2010; 148 (6): 925-37
• LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK, Pollack JR. Cancer Res. 2010; 70 (6): 2296-306
• Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. Cancer Res. 2010; 70 (16): 6477-85
• Comparative genomic hybridization on spotted oligonucleotide microarrays. Kim YH, Pollack JR. Methods Mol Biol. 2009: 556 21-32
• DNA microarray technology. Introduction. Pollack JR, Methods Mol Biol. 2009: 556 1-6
• Integration of diverse microarray data types. Salari K, Pollack JR. Methods Mol Biol. 2009: 556 205-16
• Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, Kwei KA, Hernandez-Boussard T, Wang P, Gazdar AF, Minna JD, Pollack JR. PLoS One. 2009; 4 (7): e6146
• An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Bullinger L, Döhner K, Kranz R, Stirner C, Fröhling S, Scholl C, Kim YH, Schlenk RF, Tibshirani R, Döhner H, Pollack JR. Blood. 2008; 111 (9): 4490-5
• CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer. Bergamaschi A, Kim YH, Kwei KA, La Choi Y, Bocanegra M, Langerød A, Han W, Noh DY, Huntsman DG, Jeffrey SS, Børresen-Dale AL, Pollack JR. Mol Oncol. 2008; 2 (4): 327-39
• ESR1 gene amplification in breast cancer: a common phenomenon? Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, Noh DY, Salari K, Joosse SA, Reyal F, Lingjaerde OC, Kristensen VN, Børresen-Dale AL, Pollack J, van de Vijver MJ. Nat Genet. 2008; 40 (7): 807-8; author reply 810-2
• Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. Kwei KA, Bashyam MD, Kao J, Ratheesh R, Reddy EC, Kim YH, Montgomery K, Giacomini CP, Choi YL, Chatterjee S, Karikari CA, Salari K, Wang P, Hernandez-Boussard T, Swarnalata G, van de Rijn M, Maitra A, Pollack JR. PLoS Genet. 2008; 4 (5): e1000081
• Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Kwei KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, Salari K, Lee J, Choi YL, Sato M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, Minna JD, Pollack JR. Oncogene. 2008; 27 (25): 3635-40
• Identification of candidate prostate cancer genes through comparative expression-profiling of seminal vesicle. Thompson M, Lapointe J, Choi YL, Ong DE, Higgins JP, Brooks JD, Pollack JR. Prostate. 2008; 68 (11): 1248-56
• Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers. Dumur CI, Lyons-Weiler M, Sciulli C, Garrett CT, Schrijver I, Holley TK, Rodriguez-Paris J, Pollack JR, Zehnder JL, Price M, Hagenkord JM, Rigl CT, Buturovic LJ, Anderson GG, Monzon FA. J Mol Diagn. 2008; 10 (1): 67-77
• MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Möller P, Stilgenbauer S, Pollack JR, Wirth T. Blood. 2008; 112 (10): 4202-12
• hCAP-D3 expression marks a prostate cancer subtype with favorable clinical behavior and androgen signaling signature. Lapointe J, Malhotra S, Higgins JP, Bair E, Thompson M, Salari K, Giacomini CP, Ferrari M, Montgomery K, Tibshirani R, van de Rijn M, Brooks JD, Pollack JR. Am J Surg Pathol. 2008; 32 (2): 205-9
• A perspective on DNA microarrays in pathology research and practice. Pollack JR, Am J Pathol. 2007; 171 (2): 375-85
• A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Lapointe J, Kim YH, Miller MA, Li C, Kaygusuz G, van de Rijn M, Huntsman DG, Brooks JD, Pollack JR. Mod Pathol. 2007; 20 (4): 467-73
• Evolutionary and biomedical insights from the rhesus macaque genome. Gibbs RA, Rogers J, Katze MG, Bumgarner R, Weinstock GM, Mardis ER, Remington KA, Strausberg RL, Venter JC, Wilson RK, Batzer MA, Bustamante CD, Eichler EE, Hahn MW, Hardison RC, Makova KD, Miller W, Milosavljevic A, Palermo RE, Siepel A, Sikela JM, Attaway T, Bell S, Bernard KE, Buhay CJ, Chandrabose MN, Dao M, Davis C, Delehaunty KD, Ding Y, Dinh HH, Dugan-Rocha S, Fulton LA, Gabisi RA, Garner TT, Godfrey J, Hawes AC, Hernandez J, Hines S, Holder M, Hume J, Jhangiani SN, Joshi V, Khan ZM, Kirkness EF, Cree A, Fowler RG, Lee S, Lewis LR, Li Z, Liu YS, Moore SM, Muzny D, Nazareth LV, Ngo DN, Okwuonu GO, Pai G, Parker D, Paul HA, Pfannkoch C, Pohl CS, Rogers YH, Ruiz SJ, Sabo A, Santibanez J, Schneider BW, Smith SM, Sodergren E, Svatek AF, Utterback TR, Vattathil S, Warren W, White CS, Chinwalla AT, Feng Y, Halpern AL, Hillier LW, Huang X, Minx P, Nelson JO, Pepin KH, Qin X, Sutton GG, Venter E, Walenz BP, Wallis JW, Worley KC, Yang SP, Jones SM, Marra MA, Rocchi M, Schein JE, Baertsch R, Clarke L, Csürös M, Glasscock J, Harris RA, Havlak P, Jackson AR, Jiang H, Liu Y, Messina DN, Shen Y, Song HX, Wylie T, Zhang L, Birney E, Han K, Konkel MK, Lee J, Smit AF, Ullmer B, Wang H, Xing J, Burhans R, Cheng Z, Karro JE, Ma J, Raney B, She X, Cox MJ, Demuth JP, Dumas LJ, Han SG, Hopkins J, Karimpour-Fard A, Kim YH, Pollack JR, Vinar T, Addo-Quaye C, Degenhardt J, Denby A, Hubisz MJ, Indap A, Kosiol C, Lahn BT, Lawson HA, Marklein A, Nielsen R, Vallender EJ, Clark AG, Ferguson B, Hernandez RD, Hirani K, Kehrer-Sawatzki H, Kolb J, Patil S, Pu LL, Ren Y, Smith DG, Wheeler DA, Schenck I, Ball EV, Chen R, Cooper DN, Giardine B, Hsu F, Kent WJ, Lesk A, Nelson DL, O'brien WE, Prüfer K, Stenson PD, Wallace JC, Ke H, Liu XM, Wang P, Xiang AP, Yang F, Barber GP, Haussler D, Karolchik D, Kern AD, Kuhn RM, Smith KE, Zwieg AS. Science. 2007; 316 (5822): 222-34
• Gene copy number variation spanning 60 million years of human and primate evolution. Dumas L, Kim YH, Karimpour-Fard A, Cox M, Hopkins J, Pollack JR, Sikela JM. Genome Res. 2007; 17 (9): 1266-77
• Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Bullinger L, Rücker FG, Kurz S, Du J, Scholl C, Sander S, Corbacioglu A, Lottaz C, Krauter J, Fröhling S, Ganser A, Schlenk RF, Döhner K, Pollack JR, Döhner H. Blood. 2007; 110 (4): 1291-300
• Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR. Cancer Res. 2007; 67 (18): 8504-10
• Target discovery and validation in pancreatic cancer. Beaty RM, Gronborg M, Pollack JR, Maitra A. Methods Mol Biol. 2007: 360 57-89
• c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L, Hanna AE, Liu D, Girard L, Kim YH, Pollack JR, Minna JD, Wistuba II, Kurie JM. Oncogene. 2007; 26 (18): 2658-66
• A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. Shames DS, Girard L, Gao B, Sato M, Lewis CM, Shivapurkar N, Jiang A, Perou CM, Kim YH, Pollack JR, Fong KM, Lam CL, Wong M, Shyr Y, Nanda R, Olopade OI, Gerald W, Euhus DM, Shay JW, Gazdar AF, Minna JD. PLoS Med. 2006; 3 (12): e486
• Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, Chia S, Magliocco A, Makretsov N, Gilks B, Pollack J, Huntsman D. Gynecol Oncol. 2006; 100 (2): 264-70
• Application of genomic technologies to human prostate cancer. Li S, Bhamre S, Lapointe J, Pollack JR, Brooks JD. OMICS. 2006; 10 (3): 261-75
• Chromosome instability leaves its mark. Pollack JR, Nat Genet. 2006; 38 (9): 973-4
• Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, Tibshirani R, Minna JD, Pollack JR. Oncogene. 2006; 25 (1): 130-8
• DNA microarray and proteomic strategies for understanding alcohol action. Sikela JM, Maclaren EJ, Kim Y, Karimpour-Fard A, Cai WW, Pollack J, Hitzemann R, Belknap J, McWeeney S, Kerns RT, Downing C, Johnson TE, Grant KJ, Tabakoff B, Hoffman P, Wu CC, Miles MF. Alcohol Clin Exp Res. 2006; 30 (4): 700-8
• Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. Rücker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Fröhling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H. J Clin Oncol. 2006; 24 (24): 3887-94
• Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Bergamaschi A, Kim YH, Wang P, Sørlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Børresen-Dale AL, Pollack JR. Genes Chromosomes Cancer. 2006; 45 (11): 1033-40
• Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, Dohner K, Schlenk RF, Pollack JR, Dohner H, Bullinger L. Blood. 2006; 108 (13): 4109-17
• Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations. Rücker FG, Sander S, Döhner K, Döhner H, Pollack JR, Bullinger L. Leukemia. 2006; 20 (6): 994-1001
• RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Kao J, Pollack JR. Genes Chromosomes Cancer. 2006; 45 (8): 761-9
• A DNA microarray survey of gene expression in normal human tissues. Shyamsundar R, Kim YH, Higgins JP, Montgomery K, Jorden M, Sethuraman A, van de Rijn M, Botstein D, Brown PO, Pollack JR. Genome Biol. 2005; 6 (3): R22
• A gene expression signature of genetic instability in colon cancer. Giacomini CP, Leung SY, Chen X, Yuen ST, Kim YH, Bair E, Pollack JR. Cancer Res. 2005; 65 (20): 9200-5
• A method for calling gains and losses in array CGH data. Wang P, Kim Y, Pollack J, Narasimhan B, Tibshirani R. Biostatistics. 2005; 6 (1): 45-58
• Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart Salmon J, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP. Cancer Res. 2005; 65 (1): 226-35
• Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNA. Bredel M, Bredel C, Juric D, Kim Y, Vogel H, Harsh GR, Recht LD, Pollack JR, Sikic BI. J Mol Diagn. 2005; 7 (2): 171-82
• An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, van Laar RK, Waring PM, Zalcberg J, Ward R, Biankin AV, Sutherland RL, Henshall SM, Fong K, Pollack JR, Bowtell DD, Holloway AJ. Cancer Res. 2005; 65 (10): 4031-40
• Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, Karikari CA, Tibshirani R, Maitra A, Pollack JR. Neoplasia. 2005; 7 (6): 556-62
• Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model. Sander S, Bullinger L, Karlsson A, Giuriato S, Hernandez-Boussard T, Felsher DW, Pollack JR. Oncogene. 2005; 24 (40): 6101-7
• Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack JR, Brooks JD. Prostate. 2005; 63 (2): 187-97
• Genomics in myeloid leukemias: an array of possibilities. Bullinger L, Döner H, Pollack JR. Rev Clin Exp Hematol. 2005; 9 (1): E2
• The retinoic acid synthesis gene ALDH1a2 is a candidate tumor suppressor in prostate cancer. Kim H, Lapointe J, Kaygusuz G, Ong DE, Li C, van de Rijn M, Brooks JD, Pollack JR. Cancer Res. 2005; 65 (18): 8118-24
• Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Proc Natl Acad Sci U S A. 2004; 101 (3): 811-6
• High-resolution array-based comparative genomic hybridization for distinguishing paraffin-embedded Spitz nevi and melanomas. Harvell JD, Kohler S, Zhu S, Hernandez-Boussard T, Pollack JR, van de Rijn M. Diagn Mol Pathol. 2004; 13 (1): 22-5
• Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, Milchgrub S, Smith AL, Souza RF, Gilbey L, Zhang X, Gandia K, Vaughan MB, Wright WE, Gazdar AF, Shay JW, Minna JD. Cancer Res. 2004; 64 (24): 9027-34
• Lineage-specific gene duplication and loss in human and great ape evolution. Fortna A, Kim Y, MacLaren E, Marshall K, Hahn G, Meltesen L, Brenton M, Hink R, Burgers S, Hernandez-Boussard T, Karimpour-Fard A, Glueck D, McGavran L, Berry R, Pollack J, Sikela JM. PLoS Biol. 2004; 2 (7): E207
• Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. Bullinger L, Döhner K, Bair E, Fröhling S, Schlenk RF, Tibshirani R, Döhner H, Pollack JR. N Engl J Med. 2004; 350 (16): 1605-16
• Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. Linn SC, West RB, Pollack JR, Zhu S, Hernandez-Boussard T, Nielsen TO, Rubin BP, Patel R, Goldblum JR, Siegmund D, Botstein D, Brown PO, Gilks CB, van de Rijn M. Am J Pathol. 2003; 163 (6): 2383-95
• Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, Brooks JD. Am J Pathol. 2003; 162 (3): 925-32
• Gene expression profiling in prostate cancer cells with Akt activation reveals Fra-1 as an Akt-inducible gene. Tiwari G, Sakaue H, Pollack JR, Roth RA. Mol Cancer Res. 2003; 1 (6): 475-84
• Parallel analysis of gene copy number and expression using cDNA microarrays. Pollack JR, Methods Mol Biol. 2003: 224 89-97
• The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Jeffrey SS, Pollack JR. Breast Cancer Res. 2003; 5 (6): 320-8
• A transcriptional response to Wnt protein in human embryonic carcinoma cells. Willert J, Epping M, Pollack JR, Brown PO, Nusse R. BMC Dev Biol. 2002: 2 8
• Challenges in developing a molecular characterization of cancer. Pollack JR, Van de Rijn M, Botstein D. Semin Oncol. 2002; 29 (3): 280-5
• Characterizing the physical genome. Pollack JR, Iyer VR. Nat Genet. 2002: 32 Suppl 515-21
• Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Pollack JR, Sørlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Børresen-Dale AL, Brown PO. Proc Natl Acad Sci U S A. 2002; 99 (20): 12963-8
• Molecular characterisation of soft tissue tumours: a gene expression study. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, Zhu S, Fero M, Sherlock G, Pollack JR, Brown PO, Botstein D, van de Rijn M. Lancet. 2002; 359 (9314): 1301-7
• Physical mapping of genes in somatic cell radiation hybrids by comparative genomic hybridization to cDNA microarrays. Lin JY, Pollack JR, Chou FL, Rees CA, Christian AT, Bedford JS, Brown PO, Ginsberg MH. Genome Biol. 2002; 3 (6): RESEARCH0026
• Molecular portraits of human breast tumours. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Nature. 2000; 406 (6797): 747-52
• Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Pollack JR, Perou CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, Jeffrey SS, Botstein D, Brown PO. Nat Genet. 1999; 23 (1): 41-6